Trial Outcomes & Findings for Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients (NCT NCT03348683)

NCT ID: NCT03348683

Last Updated: 2020-01-07

Results Overview

The time of induction (based on time of foley balloon placement for cervical ripening or misoprostol administration) to the time of delivery of the infant.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

240 participants

Primary outcome timeframe

average of 24 hours

Results posted on

2020-01-07

Participant Flow

First enrollment 12-11-2017, final enrollment 12/11/2018. Enrollment occurred on the labor floor of the Mount Sinai Hospital.

Participant milestones

Participant milestones
Measure
Propranolol
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
Placebo
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
Overall Study
STARTED
121
119
Overall Study
COMPLETED
121
119
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Propranolol
n=121 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
Placebo
n=119 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
Total
n=240 Participants
Total of all reporting groups
Age, Continuous
31.70 years
STANDARD_DEVIATION 5.72 • n=99 Participants
31.61 years
STANDARD_DEVIATION 6.37 • n=107 Participants
31.66 years
STANDARD_DEVIATION 6.04 • n=206 Participants
Sex: Female, Male
Female
121 Participants
n=99 Participants
119 Participants
n=107 Participants
240 Participants
n=206 Participants
Sex: Female, Male
Male
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
16 Participants
n=99 Participants
5 Participants
n=107 Participants
21 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
16 Participants
n=99 Participants
11 Participants
n=107 Participants
27 Participants
n=206 Participants
Race (NIH/OMB)
White
72 Participants
n=99 Participants
83 Participants
n=107 Participants
155 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
17 Participants
n=99 Participants
20 Participants
n=107 Participants
37 Participants
n=206 Participants
Body Mass Index (BMI) at admission
29.04 kg/m^2
STANDARD_DEVIATION 5.34 • n=99 Participants
28.89 kg/m^2
STANDARD_DEVIATION 4.40 • n=107 Participants
28.97 kg/m^2
STANDARD_DEVIATION 4.89 • n=206 Participants
Gestational Age (GA) at admission
39.7 months
n=99 Participants
40.1 months
n=107 Participants
40.0 months
n=206 Participants
Married
94 Participants
n=99 Participants
97 Participants
n=107 Participants
191 Participants
n=206 Participants
Private Insurance
101 Participants
n=99 Participants
93 Participants
n=107 Participants
194 Participants
n=206 Participants
In vitro Fertilization (IVF)
18 Participants
n=99 Participants
19 Participants
n=107 Participants
37 Participants
n=206 Participants
Fetal Growth Restriction
8 Participants
n=99 Participants
3 Participants
n=107 Participants
11 Participants
n=206 Participants
Tobacco Use
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants

PRIMARY outcome

Timeframe: average of 24 hours

Population: N=154 - only those who delivered vaginally

The time of induction (based on time of foley balloon placement for cervical ripening or misoprostol administration) to the time of delivery of the infant.

Outcome measures

Outcome measures
Measure
Propranolol
n=75 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
Placebo
n=79 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
Time From Beginning of Induction to Delivery
13.8 hours
Standard Deviation 5.4
14.3 hours
Standard Deviation 5.3

SECONDARY outcome

Timeframe: average of 24 hours

Number of various mode of delivery - count of Vaginal delivery, vacuum assisted vaginal delivery, forceps assisted vaginal delivery, cesarean section

Outcome measures

Outcome measures
Measure
Propranolol
n=121 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
Placebo
n=119 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
Number of Participants With Various Mode of Delivery
Spontaneous vaginal delivery
64 Participants
61 Participants
Number of Participants With Various Mode of Delivery
Vacuum assisted vaginal delivery
3 Participants
10 Participants
Number of Participants With Various Mode of Delivery
Forceps assisted vaginal delivery
8 Participants
8 Participants
Number of Participants With Various Mode of Delivery
Cesarean section
46 Participants
40 Participants

SECONDARY outcome

Timeframe: average of 24 hours

Time of latent labor defined as \<6cm of cervical dilation.

Outcome measures

Outcome measures
Measure
Propranolol
n=121 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
Placebo
n=119 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
Duration of Latent
11.0 hours
Standard Deviation 5.0
11.2 hours
Standard Deviation 4.5

SECONDARY outcome

Timeframe: average of 24 hours

Composite maternal morbidity score consists of a count of postpartum hemorrhage, transfusion, hysterectomy, placental abruption, chorioamnionitis, shoulder dystocia, episiotomy, higher order laceration, and ICU admission. The composite score was computed as a score of 1 for any indication of maternal morbidity, that is the participant experienced at least one maternal morbidity, and the components are given equal weights. Participants who had no evidence of the predefined maternal morbidities are subsequently given a score of 0. The minimum is 0 and maximum is 1.

Outcome measures

Outcome measures
Measure
Propranolol
n=121 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
Placebo
n=119 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
Number of Participants With Maternal Morbidity Composite Score = 1
35 Participants
49 Participants

SECONDARY outcome

Timeframe: 30 minutes from drug administration

Greater than 500cc of blood expelled during a vaginal delivery or greater than 1000cc of blood expelled during a cesarean section

Outcome measures

Outcome measures
Measure
Propranolol
n=121 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
Placebo
n=119 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
Number of Participants With Postpartum Hemorrhage
15 Participants
26 Participants

SECONDARY outcome

Timeframe: 30 minutes from drug administration

Count of fetus with fetal heart rate decelerations within 30 minutes of study drug administration

Outcome measures

Outcome measures
Measure
Propranolol
n=121 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
Placebo
n=119 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
Number of Fetus With Heart Rate Decelerations
15 Participants
13 Participants

SECONDARY outcome

Timeframe: 30 minutes from drug administration

Count of fetus with fetal bradycardia (\<110bpm for \>10 minutes within 30 minutes of study drug administration)

Outcome measures

Outcome measures
Measure
Propranolol
n=121 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
Placebo
n=119 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
Number of Fetus With Fetal Bradycardia
1 Participants
0 Participants

SECONDARY outcome

Timeframe: Day 1

Composite neonatal outcome score was for any of the following morbidity: Neonatal Intensive Care Unit (NICU) admission, respiratory support (CPAP, nasal cannula, intubation), culture proven sepsis, radiographically proven intracranial hemorrhage, necrotizing enterocolitis, hypoglycemia (for those infants who had sugar checked), and neonatal death. The composite score was computed as a score of 1 for any indication of neonatal morbidity - neonates who experienced at least one morbidity and the components are given equal weights. Patients who had no evidence of the predefined neonatal morbidities are subsequently given a score of 0. The minimum is 0 and maximum is 1.

Outcome measures

Outcome measures
Measure
Propranolol
n=121 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
Placebo
n=119 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
Number of Neonates With Neonatal Outcome Composite Score = 1
21 Participants
28 Participants

SECONDARY outcome

Timeframe: Day 1

Population: This population includes the neonates who had heelsticks to check their blood glucose.

Neonatal outcome - Number of neonates with hypoglycemia (blood glucose \<50). This population includes only the neonates who had heelsticks to check their blood glucose, which is not a universal practice and was not required by the protocol or IRB. The neonates included were those who met the nursery's risk-based protocol to check blood glucose after birth (ex: infants of diabetic mothers, fetal growth restriction, macrosomia, or symptoms suggestive of hypoglycemia)

Outcome measures

Outcome measures
Measure
Propranolol
n=45 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
Placebo
n=49 Participants
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
Number of Neonates With Hypoglycemia
11 Participants
8 Participants

Adverse Events

Propranolol

Serious events: 1 serious events
Other events: 16 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 13 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Propranolol
n=121 participants at risk
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
Placebo
n=119 participants at risk
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
Pregnancy, puerperium and perinatal conditions
Fetal bradycardia
0.83%
1/121 • 24 hours
0.00%
0/119 • 24 hours

Other adverse events

Other adverse events
Measure
Propranolol
n=121 participants at risk
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of propranolol 2mg of IV push
Placebo
n=119 participants at risk
After induction was started with Foley or misoprostol placement, 30 minutes passed before administration of an equivalent quantity in milliliters of IV normal saline
Vascular disorders
Maternal hypotension
0.83%
1/121 • 24 hours
0.00%
0/119 • 24 hours
Pregnancy, puerperium and perinatal conditions
Fetal heart rate decelerations
12.4%
15/121 • 24 hours
10.9%
13/119 • 24 hours

Additional Information

Dr. Catherine A Bigelow

Icahn School of Medicine at Mount Sinai

Phone: 651-206-9069

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place